OBJECTIVES: Skin and soft tissue infections (SSTI) are common and complicated SSTIs (cSSTI) is the more extreme end of this clinical spectrum. The aim of this analysis is to estimate the budget impact of Linezolid in the treatment of cSSTI in Colombia. METHODS: A model was built with a horizon of three years. The comparators were: Linezolid (600mg IV/twice day) switch (600 orally/twice day) compared with Vancomycin (1 g IV/ twice day), Daptomycin (4 mg IV/kg/day) and Tigecycline (100 mg IV followed by 50 mg twice day). The analysis used the third payer perspective including only direct medical costs. Costs were taken from health care institutions. Resource use and costs (drug acquisition, inpatient stay, healthcare professional visits, and lab tests). Costs were expressed in 2012 $ US. The calculation of patients likely to be treatment was estimate using data published in the literature on the incidence of patients hospitalized for SSTI and the percentage of methicillin-resistant Staphylococcus aureus (MRSA) in cSSTI, this data were applied the Colombian population projected by the national administrative department of statistics for 2012. Univariate sensitivity analyses were performed. RESULTS: With an incidence of 0.16 hospitalizations for SSTI per 10,000 hospital visits per year, and considering the market share growth of Linezolid from 15% to 35% over 3 years, the model showed a reduction of approximately $ US 15,609,105.97 in total costs for disease treatment . If the market share of Linezolid would be increased 1% there could be savings for $ US 460,428.26 (first year). CONCLUSIONS: Linezolid is a favorable alternative for the treatment of cSSTI, considering the lower cost of treatment per patient ($ US 8,226.25) per year compared with other available antimicrobial therapies, which would mean relevant savings in the context of health system in this country.